Sun Pharma's Groundbreaking Acquisition: A New Era in Global Healthcare

Sun Pharmaceutical Industries Ltd's acquisition of Organon & Co., valued at USD 11.75 billion, marks one of the largest foreign acquisitions by an Indian firm. This strategic move enhances Sun Pharma's global footprint, positioning it among the top 25 pharmaceutical companies and expanding its influence in women's health and branded generics.

Sun Pharmaceutical Industries Ltd announced a significant, all-cash acquisition of U.S.-based Organon & Co., valued at an enterprise valuation of USD 11.75 billion. The deal, one of the largest overseas acquisitions by an Indian firm, positions Sun Pharma among the top 25 global pharmaceutical companies, expanding its reach in established brands and branded generics.

Organon, a global healthcare company with an emphasis on women's health, was formed through a spinoff from Merck in 2021. The acquisition facilitates Sun Pharma's global expansion, as the company is now poised to create a stronger and diversified platform, complementing its vision of 'reaching people and touching lives'.

Upon successful completion of the deal in 2027, Sun Pharma will become a top-three company in global women's health and the 7th largest global biosimilar player. The agreement requires regulatory approvals and is backed by both companies' boards, promising a substantial impact on the pharmaceutical landscape.